Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Table 2 Changes in the variables from baseline to 52 weeks

	Anagliptin (n = 177)			Sitagliptin (n = 176)			P value^a
	Baseline	52 week	P value	Baseline	52 week	P value	P value^a
Low-density lipoprotein cholesterol, mg/dL	112 ± 22	108 ± 22	0.01	109 ± 22	111 ± 22	0.23	0.01
Total cholesterol, mg/dL	191 ± 29	186 ± 27	0.03	186 ± 28	190 ± 28	0.02	0.001
Triglyceride, mg/dL	148 ± 77	155 ± 84	0.42	129 ± 68	136 ± 82	0.19	0.80
Adiponectin, μg/mL	4.4 ± 4.4	4.7 ± 5.2	0.01	4.7 ± 4.9	5.0 ± 5.8	0.14	0.23
Aspartate aminotransferase, IU/L	28 ± 18	27 ± 18	0.60	23 ± 9	26 ± 19	0.02	0.05
Alanine aminotransferase, IU/L	29 ± 19	28 ± 20	0.40	22 ± 13	23 ± 15	0.41	0.24
Platelets, 10⁴/μL	22 ± 6	21 ± 6	0.14	22 ± 5	22 ± 6	0.92	0.23
FIB-4 index	1.8 ± 0.9	1.8 ± 0.9	0.36	1.7 ± 0.8	1.9 ± 1.3	0.03	0.19
Lipoprotein (a), mg/dL^b	11.2 ± 9.4	11.3 ± 9.1	0.81	14.0 ± 11.6	14.4 ± 12.3	0.39	0.65
Malondialdehyde-modified low-density lipoprotein, U/L^b	162.9 ± 51.3	153.5 ± 50.9	0.05	152.3 ± 42.4	153.6 ± 45.6	0.80	0.13
Remnant-like particle cholesterol, mmol/L^b	7.6 ± 4.9	8.8 ± 6.8	0.07	6.6 ± 4.5	7.7 ± 5.4	0.04	0.91

Data are expressed as mean ± standard deviation
^aFor group difference in absolute change from baseline to 52 weeks
^bIndicates measured in randomly selected cohort (n =50 on anagliptin, 50 on sitagliptin)

ISSN: 1475-2840